Since the onset of the global COVID-19 pandemic, there has been much discussion about the advantages and disadvantages of ongoing chronic drug therapies in SARS-CoV-2-positive patients. These discussions include also statins treatment. The statins are among the most widely used drugs in the global population. Statins aim to lower cholesterol, which is essential for many biological processes but can lead to heart disease if levels are too high; however, also the pleiotropic effects of statins are well known. So could the anti-inflammatory or the potential antiviral effects of statins be helpful in avoiding extreme inflammation and severity in COVID-19? To date, there are conflicting opinions on the effects of statins in the course of COVID-19 infection. The aim of this article is to describe the molecular and pharmacological basis of the pleiotropic effects of statins that could be more involved in the fight against COVID-19 infection and to investigate the current epidemiological evidence in the literature on the current and important topic.

自全球 COVID-19 大流行开始以来，关于 SARS-CoV-2 阳性患者正在进行的慢性药物治疗的优缺点的讨论很多。这些讨论还包括他汀类药物治疗。他汀类药物是全球人群中使用最广泛的药物之一。他汀类药物旨在降低胆固醇，这是许多生物过程必不可少的，但如果水平过高会导致心脏病；然而，他汀类药物的多效作用也是众所周知的。那么他汀类药物的抗炎或潜在抗病毒作用是否有助于避免 COVID-19 的极端炎症和严重程度？迄今为止，关于他汀类药物在 COVID-19 感染过程中的作用存在不同意见。